VOR BIOPHARMA INC. - COMMON STOCK

Vor Bio to Present at Keystone Symposia Precision Genome Engineering Meeting

25 Apr 2022 08:00:01 By Nasdaq GlobeNewswire

Vor Bio Announces Retirement of Chief Medical Officer

14 Apr 2022 16:15:00 By Nasdaq GlobeNewswire

Vor Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update

14 Mar 2022 16:30:15 By Nasdaq GlobeNewswire

Vor to Participate in Three Upcoming Investor Conferences

28 Feb 2022 08:00:02 By Nasdaq GlobeNewswire

Vor to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

11 Feb 2022 08:00:00 By Nasdaq GlobeNewswire

Vor to Participate in Two Upcoming Investor Conferences

04 Jan 2022 08:00:02 By Nasdaq GlobeNewswire

Vor to Participate in the JMP Securities Hematology and Oncology Summit

29 Nov 2021 08:00:01 By Nasdaq GlobeNewswire

Vor to Participate in Piper Sandler 33rd Virtual Annual Healthcare Conference

19 Nov 2021 16:01:00 By Nasdaq GlobeNewswire

Vor Reports Third Quarter 2021 Financial Results and Provides Company Update

10 Nov 2021 16:10:00 By Nasdaq GlobeNewswire

Vor to Present New Data on its Cell and Genome Engineering Platform at SITC Annual Meeting

09 Nov 2021 08:30:00 By Nasdaq GlobeNewswire

Vor to Participate in Two Upcoming Investor Conferences

08 Nov 2021 08:00:02 By Nasdaq GlobeNewswire

Vor to Present New Platform and Preclinical Data at ASH

04 Nov 2021 09:15:00 By Nasdaq GlobeNewswire

Vor to Present Data from its Novel Cell and Genome Engineering Platform at ESGCT

19 Oct 2021 07:00:01 By Nasdaq GlobeNewswire

Vor Strengthens Leadership Team with Addition of Dr. Veit Schmelmer as SVP of Program and Alliance Management

12 Oct 2021 08:00:02 By Nasdaq GlobeNewswire

VOR33 Granted U.S. FDA Fast Track Designation for AML

09 Sep 2021 08:00:03 By Nasdaq GlobeNewswire

Vor to Participate in Three Upcoming Investor Conferences

02 Sep 2021 08:00:00 By Nasdaq GlobeNewswire

Vor Reports Second Quarter 2021 Financial Results and Provides Company Update

09 Aug 2021 16:05:01 By Nasdaq GlobeNewswire

Vor Biopharma Announces Collaboration with Janssen to Develop Engineered Hematopoietic Stem Cell Transplants Combined With a Bi-Specific Antibody Therapy for Acute Myeloid Leukemia (AML)

08 Jul 2021 08:00:01 By Nasdaq GlobeNewswire

Vor to Build-Out State-of-the-Art Clinical Manufacturing Facility Capable of Supporting Multiple Cell Therapy Programs

17 Jun 2021 08:00:01 By Nasdaq GlobeNewswire

Vor Biopharma Names Matthew R. Patterson as Chairman and Promotes Tania Philipp

11 Jun 2021 08:00:00 By Nasdaq GlobeNewswire